Raymond James Financial
DGX icon

Raymond James Financial’s Quest Diagnostics DGX Stock Holding History

Raymond James Financial’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$89.8M Sell
458,455
-4,827
-1% -$938K 0.03% 555
2025
Q4 		$80.4M Buy
463,282
+5,245
+1% +$955K 0.03% 597
2025
Q3 		$87.3M Sell
458,037
-52,590
-10% -$9.33M 0.03% 551
2025
Q2 		$91.7M Sell
510,627
-38,615
-7% -$6.71M 0.03% 510
2025
Q1 		$92.9M Buy
549,242
+102,159
+23% +$16.8M 0.04% 461
2024
Q4 		$67.4M Buy
+447,083
New +$69.5M 0.02% 573

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Raymond James Financial's DGX Position: Q1 2026 in Review

Raymond James Financial reduced its Quest Diagnostics (DGX) stake by 1% in Q1 2026, selling an estimated $938K and leaving 458,455 shares worth $89.8M. The position accounts for 0.03% of the portfolio, ranked #555.

Raymond James Financial first reported a position in DGX in Q4 2024 and has held it in 6 quarters since. The position peaked at $92.9M in Q1 2025. 1,066 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Raymond James Financial held 458,455 shares of Quest Diagnostics worth $89.8M as of Q1 2026.
  • Raymond James Financial sold 4,827 Quest Diagnostics shares in Q1 2026, an estimated $938K.
  • Quest Diagnostics made up 0.03% of Raymond James Financial's portfolio in Q1 2026, its #555 holding.
  • Raymond James Financial first reported a position in Quest Diagnostics in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Quest Diagnostics position peaked at $92.9M in Q1 2025.
  • 1,066 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.